ATM rs11212617 — Where DNA Repair Meets Longevity Pharmacology
The ataxia telangiectasia mutated (ATM) gene encodes one of the master regulators of the cellular DNA damage
response — a kinase that springs into action when double-strand DNA breaks are detected, coordinating cell
cycle arrest, DNA repair, and, when damage is irreparable, programmed cell death. What makes ATM central to
longevity biology is what it does downstream: ATM activates
AMPK | AMP-activated protein kinase — the cell's master energy sensor, activated when ADP/AMP ratios rise,
and the primary target of metformin's longevity effects,
which in turn inhibits mTOR and triggers autophagy. This positions ATM not just as a DNA repair enzyme but
as a node connecting genomic stability to the metabolic hallmarks of aging.
The rs11212617 variant sits in an intron within the ATM locus on chromosome 11q22, inside a 340 kb linkage
disequilibrium block. The C allele is associated with enhanced metformin response, suggesting it may modify
how efficiently ATM activates AMPK under metabolic stress — the same pathway that metformin engages when
it inhibits mitochondrial complex I and raises the AMP:ATP ratio.
The Mechanism
Metformin's primary action is inhibition of mitochondrial complex I in the electron transport chain, raising
the cellular AMP:ATP ratio and directly activating AMPK. But metformin also appears to engage the ATM-AMPK
axis: experimental work using ATM inhibitor KU-55933 in rat hepatoma cells | Zhou K et al. Common variants
near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics,
2011 showed attenuated AMPK phosphorylation in response to
metformin when ATM was blocked. The mechanistic interpretation was complicated by a subsequent finding that
KU-55933 also inhibits OCT1 (a metformin transporter), potentially reducing intracellular metformin rather
than directly blocking an ATM-AMPK signal. Whether ATM acts directly on AMPK, indirectly through modulating
DNA damage-sensing cascades that converge on AMPK, or primarily via effects on metformin transport remains
an active question.
What is established is that activated ATM phosphorylates and stabilizes SIRT6, and that ATM activity also
restrains mTORC1 via the AMPK-TSC2 pathway after DNA damage.
Boosting ATM activity extended lifespan in mouse models of progeria | Qian M et al. Boosting ATM activity
alleviates aging and extends lifespan in a mouse model of progeria. eLife,
2018,
and ATM-deficient mice show accelerated metabolic dysfunction and premature aging — establishing the gene's
role in organismal longevity beyond its classic function in cancer suppression.
The Evidence
The landmark GWAS by Zhou et al. 2011 | Common variants near ATM are associated with glycemic response to
metformin in type 2 diabetes. Nature Genetics discovered
rs11212617 by scanning 1,024 Scottish type 2 diabetes patients on metformin. In the combined meta-analysis
of 3,920 patients, the C allele reached genome-wide significance (P=2.9×10⁻⁹) for metformin treatment
success (achieving HbA1c below 7%), with an odds ratio of 1.35 (95% CI 1.22–1.49). Each additional C allele
correlated with 0.11% lower HbA1c on metformin treatment (P=6.6×10⁻⁷).
Van Leeuwen et al. 2012 | A gene variant near ATM is significantly associated with metformin treatment
response in type 2 diabetes: a replication and meta-analysis of five cohorts.
Diabetologia replicated the association across three new
cohorts and declared rs11212617 the first robustly replicated common pharmacogenetic variant for metformin
(combined five-cohort OR 1.25, P=7.8×10⁻⁶).
However, Florez et al. 2012 | The C allele of ATM rs11212617 does not associate with metformin response
in the Diabetes Prevention Program. Diabetes Care failed to
confirm the association in 2,994 participants treated with metformin for diabetes prevention (HR 1.17,
P=0.13). The authors note an important distinction: the DPP enrolled prediabetic individuals while the
discovery GWAS enrolled established type 2 diabetics — the biological context of metformin's action may
differ substantially between these populations. Multiple other studies in European, South Asian, and East
Asian populations have found inconsistent replication, suggesting the association may be population-specific
or context-dependent.
In an independent direction, Cuyàs et al. 2019 | METTEN trial — Frontiers in Oncology
found that C allele carriers among HER2-positive breast cancer patients had a 7.94-fold higher probability
of pathological complete response when treated with neoadjuvant metformin (p=0.011), while no association
existed in the control arm — extending the variant's pharmacogenetic relevance to cancer treatment.
The mixed replication record is reflected in the moderate evidence level: the initial GWAS signal is robust
within European type 2 diabetes cohorts, but context-dependence, population variation, and an unresolved
molecular mechanism prevent elevation to strong.
Practical Actions
The core implication of rs11212617 is pharmacogenetic: C allele carriers — both AC heterozygotes and CC
homozygotes — appear to show improved glycemic response to metformin in the context of established type 2
diabetes. For individuals with AA genotype who are prescribed metformin, awareness that this variant may
confer reduced metformin efficacy is worth discussing with a clinician, particularly if glycemic targets
are not met at standard doses.
Beyond pharmacogenetics, the ATM pathway connects to the same AMPK-mTOR axis that underlies caloric
restriction and intermittent fasting biology. The
TAME trial (Targeting Aging with Metformin) is currently testing
whether metformin can extend healthspan in non-diabetic older adults specifically through these longevity
pathways. Individual rs11212617 genotype may ultimately predict differential benefit even in that
prevention context.
Interactions
rs11212617 operates within the same AMPK-mTOR axis as rs2295080 (MTOR promoter variant). Individuals
carrying both the ATM rs11212617 A allele (reduced ATM-AMPK coupling) and MTOR rs2295080 TT genotype
(highest mTOR expression) would face a compound disadvantage: reduced capacity to activate AMPK through the
ATM route combined with elevated constitutive mTOR activity. This biologically plausible interaction has
not been formally tested in a published combined-genotype study. rs2802292 (FOXO3) is also a longevity
pathway partner: FOXO3 activity is downstream of AMPK and upstream mTOR signaling, making all three
variants part of the same regulatory circuit linking DNA damage response to cellular aging.
All genotypes
Common genotype — standard metformin response without the C allele pharmacogenetic advantage
You have two copies of the A allele at rs11212617, the most common configuration in European populations (approximately 28% of individuals). This genotype does not carry the C allele that has been associated with enhanced metformin response in type 2 diabetes treatment in European GWAS and replication studies. You are likely to respond to metformin at standard doses, but without the additional glycemic benefit that C allele carriers appear to derive in the context of established type 2 diabetes. If you are prescribed metformin and glycemic targets are not met at standard doses, this genotype is worth flagging to your clinician as one factor that may be relevant to dose optimization.
Two C alleles — strongest pharmacogenetic signal for metformin response in type 2 diabetes
You carry two copies of the C allele at rs11212617, the genotype associated with the greatest improvement in metformin glycemic response in the published pharmacogenetic literature. Approximately 22% of European-ancestry individuals share this genotype. In the five-cohort replication meta-analysis (n=5,391), the association between C allele dosage and metformin success (HbA1c below 7%) was confirmed at P=7.8×10⁻⁶ with OR 1.25 per allele — giving CC homozygotes an approximately 1.56-fold higher odds of treatment success compared to AA carriers. In the METTEN breast cancer trial, C allele carriers showed a striking 7.94-fold higher probability of pathological complete response when treated with neoadjuvant metformin — an independent line of evidence that the C allele's pharmacogenetic advantage may extend beyond glucose control to metformin's anti-proliferative and ATM-mediated DNA damage effects.
One C allele — partial pharmacogenetic benefit for metformin response
You carry one copy of the C allele at rs11212617, which was associated with improved metformin glycemic response in the original GWAS and the five-cohort replication meta-analysis. The AC genotype is the most common in European populations (~50% of individuals), and the C allele shows a dose-dependent effect — one copy confers intermediate benefit between AA and CC. The association is strongest in established type 2 diabetes treated with metformin, where C allele carriers show approximately 20–35% higher odds of achieving target HbA1c below 7%. The mechanism likely involves the ATM-AMPK pathway, where your C allele may confer modestly improved coupling between ATM's DNA damage response signaling and AMPK activation — one of the routes by which metformin lowers blood glucose.